Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Canillas, Lidia
• dc.contributor.author Broquetas, Teresa
• dc.contributor.author Carrión Rodríguez, José Antonio
• dc.contributor.author Pagano, Giulia
• dc.contributor.author Soriano, Agnès
• dc.contributor.author Garrido, Esther
• dc.contributor.author Fernández, Rosa
• dc.contributor.author Viu, Ana
• dc.contributor.author Romero, Judit
• dc.contributor.author Díaz,Gemma
• dc.contributor.author Cañete Hidalgo, Nuria
• dc.contributor.author Coll Estrada, Susanna
• dc.contributor.author Naranjo‐Hans, Dolores
• dc.contributor.author Bessa Caserras, Xavier
• dc.contributor.author Garcia-Retortillo, Montserrat
• dc.contributor.author Puigvehí, Marc
• dc.date.accessioned 2022-11-22T07:52:59Z
• dc.date.available 2022-11-22T07:52:59Z
• dc.date.issued 2022
• dc.description.abstract Abnormal liver function tests (A-LFTs) during admission for coronavirus disease-19 (COVID-19) are frequent, but its evolution after COVID-19 resolution remains unexplored. We evaluated factors related to A-LFTs during COVID-19 and assessed the liver outcome after patients' discharge. This is a observational study including: (1) retrospective analysis of variables related to A-LFTs during COVID-19; and (2) follow-up evaluation with blood test, transient elastography and liver biopsy in those with persistent A-LFTs. A-LFTs were defined according to CTCAEv4.0. Among 595 patients, 366 (61.5%) showed A-LFTs. The ratio of partial pressure of oxygen and inspired oxygen fraction (P/F) below 200, ferritin ≥1000 ng/mL, male gender and antibiotic and immunomodulatory treatments were related to A-LFTs. Follow-up evaluation was performed in 153 individuals. Persistent A-LFTs at follow-up was similar in patients with/without A-LFTs during admission (14.1% vs. 4.9%, p = 0.104). Fifteen (93%) and 58 (39%) patients with/without A-LFTs at follow-up showed metabolic fatty liver disease criteria (p < 0.001), which were histologically confirmed. In conclusion, A-LFTs during COVID-19 were related to infection severity. Abnormalities remitted at follow-up in >80% of patients, and no correlation between A-LFTs at admission and at follow-up was found. Most patients with A-LFTs at follow-up had non-invasive and histologically proven fatty liver disease.
• dc.format.mimetype application/pdf
• dc.identifier.citation Canillas L, Broquetas T, Carrión JA, Pagano G, Soriano A, Garrido E, et al. Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection. J Viral Hepat. 2022 Sep; 29(9): 823-34. DOI: 10.1111/jvh.13718
• dc.identifier.doi http://dx.doi.org/10.1111/jvh.13718
• dc.identifier.issn 1352-0504
• dc.identifier.uri http://hdl.handle.net/10230/54961
• dc.language.iso eng
• dc.publisher Wiley
• dc.rights This is the peer reviewed version of the following article: anillas L, Broquetas T, Carrión JA, Pagano G, Soriano A, Garrido E, et al. Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection. J Viral Hepat. 2022 Sep; 29(9): 823-34, which has been published in final form at http://dx.doi.org/10.1111/jvh.13718. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword COVID-19
• dc.subject.keyword SARS-CoV2
• dc.subject.keyword Follow-up
• dc.subject.keyword Liver function tests
• dc.subject.keyword Metabolic-associated fatty liver disease (MAFLD)
• dc.title Follow-up evaluation of patients with liver test abnormalities detected during SARS-CoV2 infection
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion